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Abstract
Venous thromboembolism (VTE), which constitutes pulmonary embolism and deep vein thrombosis, is a
common disorder associated with significant morbidity and mortality. Landmark trials have shown that direct
oral anticoagulants (DOACs) are as effective as conventional anticoagulation with vitamin K antagonists (VKA)
in prevention of VTE recurrence and associated with less bleeding. This has paved the way for the recently
published guidelines to change their recommendations in favor of DOACs in acute and long-term treatment of
VTE in patients without cancer. The recommended treatment of VTE in cancer patients remains low-molecular-weight
heparin. The initial management of pulmonary embolism (PE) should be directed based on established risk
stratification scores. Thrombolysis is an available option for patients with hemodynamically significant PE. Recent
data suggests that low-risk patients with acute PE can safely be treated as outpatients if home circumstances
are adequate. There is lack of support for use of inferior vena cava filters in patients on anticoagulation. This
review describes the acute, long-term, and extended treatment of VTE and recent evidence on the management of
sub-segmental PE.
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Background
Venous thromboembolism (VTE), which includes deep
vein thrombosis (DVT) and pulmonary embolism (PE),
is one of the most common cardiovascular diseases
occurring for the first time in about 1 in 1000 people
[1, 2]. Its incidence rises with increasing age, for ex-
ample to about 5 per 1000 people among those over
70 years of age [3]. VTE is associated with significant
morbidity and mortality with the 30-day mortality rate
in the absence of treatment of about 3 % for DVT and
31 % for PE [4]. The long-term complications of VTE are
post-thrombotic syndrome (PTS), which occurs in 20 to
50 % of patients with DVT [5], and chronic thrombo-
embolic pulmonary hypertension (CTEPH), which occurs
in 2 to 4 % of patients with PE [6]. Patients with CTEPH
have progressive dyspnea and exercise intolerance and
those with PTS have chronic leg pain and swelling, which
in a minority of patients can progress to development of
venous ulcers. These conditions can significantly reduce
the patient’s quality of life. Furthermore, the management
VTE is associated with substantial health care costs for
not only the initial hospitalization but also for hospital
re-admissions [7, 8]. Therefore, VTE is associated with
significant morbidity and mortality.* Correspondence: schulms@mcmaster.ca
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Initial management
The initial management of patients with a PE should be
based on risk stratification of the patient into low, inter-
mediate, or high risk for 30-day mortality based on estab-
lished risk scores such as pulmonary embolism severity
index (PESI) or its simplified version (simplified PESI) [9,
10]. Low risk patients, who are hemodynamically stable,
can be treated as outpatients if home circumstances are
adequate [11, 12]. At the other extreme, patients with acute
PE and hypotension or patients with DVT-associated
phlegmasia of the lower leg should be considered for treat-
ment with thrombolytic agents [13, 14].
Oral anticoagulants
Anticoagulants are the mainstay treatment of VTE and are
given in three phases of acute, long-term (in the first
3 months), and extended treatment [14]. For many years
initial treatment was started with a parenteral anticoagu-
lant, for example low-molecular-weight heparin (LMWH),
overlapping with a vitamin K antagonist (VKA), such as
warfarin. The combination was continued for at least 5 days
until the achievement of therapeutic anticoagulation with
international normalized ratio of 2 to 3 [14]. Although con-
ventional therapy with VKAs is effective and safe, it has
some limitations including delayed onset, need for parental
daily injections, and interactions with dietary vitamin K
and numerous drugs. Over the past 5 years, 4 direct oral
anticoagulants (DOACs) have been approved for acute and
long-term treatment of VTE [15–20]. The DOACs were
compared with conventional therapy and found to be as ef-
fective in prevention of VTE recurrence and associated
with less bleeding. The recently published American Col-
lege of Chest Physicians (ACCP) guidelines have changed
their recommendations in favor of DOACs in acute and
long-term treatment of VTE in patients without cancer
[21]. In patients with cancer associated VTE, the recom-
mended anticoagulation remains LMWH over VKA [21].
The aim of this review is to (1) describe the initial man-
agement of patients with acute PE including the role of
thrombolytic agents in hemodynamically unstable patients
and at the other extreme outpatient management of low
risk patients, (2) summarize the evidence on acute, long-
term, and extended treatment of VTE comparing DOACs
versus VKA, and (3) review the recent data on the manage-
ment of sub-segmental PE and the lack of support for use
of inferior vena cava filters in patients on anticoagulation.
Review
Acute and long-term treatment of venous
thromboembolism
Thrombolytic and interventional treatment for acute venous
thromboembolism
Anticoagulant therapy alone is recommended over
thrombolysis for most patients with an acute DVT with
exception for those with extensive iliofemoral or proximal
DVT at high risk of limb ischemia [14, 21]. Thrombolytic
therapy (systemic or catheter-directed) increase clot lysis
and reduce the incidence of PTS compared to anticoagu-
lation alone [22, 23]. However, this is at the expense of
higher rate of major bleeding and no difference in rate of
recurrent VTE or mortality [22–24]. Massive proximal
DVT or iliofemoral thrombosis associated with limb-
threatening ischemia or severe symptomatic swelling may
be treated with thrombolysis. Thrombolysis can be con-
sidered only after objective diagnosis of the DVT and in a
patient with low bleeding risk. The CaVenT trial random-
ized 209 patients with iliofemoral DVT to catheter di-
rected therapy (CDT) versus anticoagulation. They found
that the patients treated with CDT had significantly less
PTS at 2 years compared with those treated with anticoa-
gulation (41 versus 56 %) [22]. Another study randomized
32 patients with iliofemoral DVT to receive either CDT or
systemic thrombolysis, followed by anticoagulation [25].
The patients who were treated with CDT had less reflux
in both the deep and superficial veins and more patients
had venous valvular competence preserved compared with
patients who underwent systemic thrombolysis. A large,
multicenter trial (the ATTRACT trial) is currently under-
way that randomizes patients to receive pharmaco-
mechanical catheter-directed thrombolysis (PCDT) plus
standard therapy with anticoagulation versus standard
therapy alone [26]. It will investigate whether PCDT
should be routinely utilized to prevent PTS in patients
with symptomatic proximal DVT [26].
Systemic thrombolysis is a widely accepted treatment
for PE in patients with persistent hypotension (e.g., sys-
tolic blood pressure <90 mmHg for 15 min) and not at
high risk of bleeding [14, 21]. The use of thrombolytic
therapy in intermediate risk patients with acute PE
associated with right ventricle (RV) dysfunction is con-
troversial. The RV dysfunction is confirmed by echo-
cardiogram or computed tomography and a positive
troponin I/T. The potential indication for thrombolysis
in this group is based on evidence that patients with se-
vere RV dysfunction have worse prognosis than those
without RV dysfunction [27]. Three recently published
trials have examined the role of systemic thrombolysis in
intermediate risk patients [28–30]. In the Moderate
Pulmonary Embolism Treated Thrombolysis (MOPETT)
trial, 121 patients were randomly assigned to receive
heparin (unfractionated or LMWH) alone or the com-
bination of tissue type plasminogen activator (tPA) plus
heparin [28]. Compared to the heparin group, treatment
with tPA resulted in lower rates of pulmonary hyperten-
sion and significantly lower pulmonary artery systolic
pressures at 28 months. The rates of bleeding, recurrent
PE, and mortality was similar in both groups [28]. In an-
other trial comparing the combination of LMWH plus
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an intravenous bolus of tenecteplase versus LMWH
alone in intermediate risk PE patients, those treated with
tenecteplase had fewer adverse outcomes and better
functional capacity at 90 days [29]. In a large multicenter
randomized trial (PEITHO), 1005 intermediate risk pa-
tients with PE were randomized to tenecteplase and hep-
arin or to heparin therapy alone [30]. Thrombolysis
therapy led to reduction in the primary composite out-
come of death or cardiovascular collapse at seven days
after randomization although it increased major bleeding
(including intracranial bleeding) with no overall gained
benefit from thrombolysis [30]. A meta-analysis of 16
trials comprising 2115 intermediate risk patients re-
ported that 59 patients would need to be treated with
thrombolysis to prevent one death, while a major bleed-
ing occurs with every 18 patients treated [13]. Further
studies are needed to identify subgroups of intermediate
risk patients who will benefit from systemic thrombo-
lytic therapy.
CDT may be used in patients with acute PE at in-
creased risk of bleeding as a lower dose of a thrombo-
lytic agent is infused directly into the pulmonary artery
via a catheter [31]. CDT is also effective in lowering pul-
monary arterial pressure and improving RV function
[32]. In a randomized controlled trial of 59 patients with
acute intermediate risk PE, ultrasound-assisted catheter-
directed thrombolysis followed by heparin was compared
to treatment with heparin alone [33]. At 24 h, CDT im-
proved the hemodynamics compared to anticoagulation.
At 90 days of follow-up, there was no difference in mor-
tality or major bleeding between the two groups [33].
Most of the evidence is limited by small sample size and
of low quality compared to the available evidence for
systemic thrombolysis. Systemic thrombolysis is there-
fore currently recommended over CDT in patients with
acute PE who are candidates for thrombolysis [21].
Outpatient treatment of venous thromboembolism
Home therapy is commonly employed for patients with
an acute DVT in clinical practice with a few exceptions.
Several randomized controlled trials and meta-analyses,
which have compared home therapy with LMWH versus
inpatient therapy with intravenous unfractionated heparin,
suggest that outpatient therapy is safe and feasible in most
patients with acute DVT [34–36]. Outpatient therapy
should not be selected for those with massive symptom-
atic DVT, high risk of bleeding, or hemodynamic instabil-
ity due to concurrent symptomatic PE [37].
The outpatient treatment of acute PE is suggested with
grade 2B evidence in the most recent ACCP guidelines
in low-risk patients with adequate home circumstances
[21]. The decision for outpatient management should take
into account the patient’s clinical condition, bleeding risk,
their preference, and the available home support. Risk
stratification scores such as PESI or simplified PESI may
be utilized to identify low-risk patients without RV dys-
function who are potential candidates for short in-hospital
stay or entirely outpatient management [11, 12, 38]. With
the recent changed recommendations in favor of DOACs
for acute and long-term VTE treatment, future research
should focus on the safety and efficacy of DOACs in out-
patient management of acute VTE.
Vitamin K antagonists versus direct oral anticoagulants
Four DOACs including dabigatran, rivaroxaban, apixa-
ban, and edoxaban were compared with conventional
therapy in the RE-COVER I and II, EINSTEIN-DVT and
PE, AMPLIFY, and Hokusai-VTE trials, respectively
[15–20]. The study design was double-blinded in all trials
except for the ENSTEIN trials, which used a prospective,
randomized, open-label, blinded end point evaluation de-
sign. The study designs and treat protocols are compared
in Table 1. The study populations were similar in these
trials. In the dabigatran and edoxaban trials, parental
anticoagulation was added to both DOAC and conven-
tional therapy arms, and after at least 5 days patients were
switched to the DOAC. Therefore, in clinical practice, pa-
tients should be initiated on parenteral anticoagulation
and either switched to dabigatran or edoxaban after 5 days
or it should be overlapped with a vitamin K antagonist. In
contrast, in the rivaroxaban and apixaban trials DOACs
were started without the need for initial parental anticoa-
gulation. The primary efficacy outcome was recurrent
VTE or VTE-related mortality in all 6 trials. The primary
safety outcome was either major bleeding or a composite
of major and clinically relevant non-major bleeding
(CRNMB). The efficacy and safety outcomes of these trials
are listed in Table 2. All of the trials excluded patients
with severe renal dysfunction, those with active bleeding
or at high risk of bleeding, and patients already on thera-
peutic anticoagulation. A recent pooled analysis of these 6
trials reported that DOACs have similar efficacy as VKA
in treatment of acute VTE and significantly lower risk of
major bleeding than VKA [39]. Recurrent VTE occurred
in 2 % of those given DOAC versus 2.2 % in patients that
received VKA (relative risk [RR] 0.90; 95 % confidence
interval [CI], 0.77 – 1.06) [39]. A 39 % reduction in risk of
major bleeding was reported in DOAC recipients com-
pared to those who received VKA therapy (RR 0.61; 95 %
CI, 0.45 – 0.83). Compared with recipients of VKA ther-
apy, intracranial bleeding, fatal bleeding, and CRNMB
were significantly reduced in the DOAC group [39]. Given
the better safety profile of DOACs with less major bleed-
ing, similar efficacy in prevention of recurrent VTE, and
the convenience of administration of DOACs, the recent
ACCP guidelines suggested DOACs over VKA for the
acute and long-term treatment of VTE in patients without
cancer [21].
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Management of VTE in patients with cancer
The major society guidelines including the ACCP,
American Society of Clinical Oncology, and the National
Comprehensive Cancer Network recommend use of
LMWH for treatment of VTE in cancer patients [21, 40,
41]. Treatment with LMWH is continued for the dur-
ation of active cancer given that the risk of recurrent
VTE can reach an annual risk of 20 % [42]. Five ran-
domized trials have compared therapy with LMWH ver-
sus warfarin in cancer patients [43–47]. The details of
these trials are outlined in Table 3. Two trials showed a
reduction in the rates of recurrent VTE using LMWH
with no effect on mortality or bleeding [44, 45], two showed
no difference in any outcome [43, 46], and the recently
published CATCH trial demonstrated a non-significant
reduction in the rate of recurrent VTE and lower risk of
CRNMB in those who received LMWH [47].
There are no published randomized trials that a priori
have compared DOACs with VKA or LMWH for treat-
ment of VTE in cancer patients. A meta-analysis of the
subsets with DVT and cancer totaling 1132 patients in
the six trials that compared DOACs versus VKA [15–20]
has been published [48]. They found similar rates of VTE
recurrence (3.9 versus 6 %; odds ratio [OR] 0.63; 95 % CI,
0.37 – 1.10) and major bleeding (3.2 versus 4.2%; OR 0.77;
95 % CI, 0.41-1.44). Although these trials included cancer
patients [15–20], they were typically not receiving active
chemotherapy or radiation. The cancer patients included
in these trials had usually completed treatment or had a
previous history of cancer and are not a true representative
Table 3 Comparison of trials on LMWH versus VKA for treatment of VTE in cancer patients
Trial Name CANTHANOX CLOT MAIN-LITE ONCENOX CATCH
Year of Publication [Ref] 2002 [43] 2003 [44] 2006 [45] 2006 [46] 2015 [47]
Design Open-label Open-label Open-label Open-label Open-label
Number of Patients 146 676 200 122 900
Treatment Protocol Enoxaparin 1.5 mg/kg
daily
Dalteparin 200 IU/kg
once daily for the
first month then





every 12 h for 5 days
then enoxaparin 1 mg/kg





3 6 3 6 6
Primary Efficacy Outcome
LMWH vs VKA (%)
Combination of major
bleeding or recurrent
VTE: 10.5 vs 21.1
Recurrent symptomatic
VTE: 9a vs 17
Recurrent
symptomatic
VTE: 7 vs 10
Recurrent symptomatic
VTE: enoxaparin 1 mg vs.




PE, or incidental VTE:
7.2 vs 10.5
Safety Bleeding Outcomes
LMWH vs VKA (%)
Major bleeding:
7 vs 16;
Fatal bleeding: 0 vs 8a
Major bleeding: 6 vs 4;






1 mg vs. 1.5 mg vs VKA :
6.5 vs 11.1 vs 2.9
Major bleeding: 2.7 vs
2.4 CRNM bleeding:
10.9a vs 15.3
CRNM clinically relevant non-major, DOAC direct oral anticoagulants, LMWH low-molecular weight heparin, PE pulmonary embolism, VKA vitamin K antagonists,
VTE venous thromboembolism
aStatistically significant difference between the two groups
Table 2 Efficacy and safety outcomes for treatment of acute VTE: DOACs versus VKA





VTE or related death:
2.4 vs 2.1a
Recurrent symptomatic




VTE: 2.1 vs 3.0a
Recurrent
symptomatic





















Major bleeding Major or CRNM bleeding
Major Bleeding
DOAC vs VKA (%)




5.6 vs 8.8 5.0 vs 7.9 8.1 vs 8.1 10.3 vs 11.4 4.3a vs 9.7 8.5a vs 10.3
DOAC direct oral anticoagulant, CRNM clinically relevant non-major, DOAC direct oral anticoagulants, VKA vitamin K antagonists, VTE venous thromboembolism
aStatistically significant difference between the two groups
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of all cancer patients. The Hokusai VTE-cancer random-
ized open label trial is currently underway and will examine
whether edoxaban is non-inferior to LMWH for treatment
of VTE in cancer patients [49].
Extended treatment of venous thromboembolism
Extended anticoagulation can be employed in patients
with unprovoked VTE to reduce the risk of recurrent
VTE if the benefit/risk ratio favors continuation of antic-
oagulation while taking into account patient’s risk of
bleeding. All DOACs except for edoxaban have been
compared with placebo in randomized trials for ex-
tended secondary VTE prevention beyond the initial
three months of anticoagulation [17, 50, 51]. The details
of these trials are compared in Table 4. All trials showed
marked superiority of the DOACs over placebo for the
prevention of recurrent VTE without significant increase
in major bleeding [17,50, 51]. However, compared to the
placebo arms, all DOACs had higher rate of CRNMB
[17, 50, 51]. Duration of extended anticoagulation was 6
to 12 months in the EINSTEIN [17] and AMPLIFY-
Extension [50] studies and 6 months in the RE-SONATE
trial [51]. Two doses of apixaban were evaluated in the
AMPLIFY-Extension trial and the rate of bleeding was
lower for apixaban 2.5 mg twice daily than 5 mg twice
daily [50]. A single regimen of rivaroxban (20 mg once
daily) and dabigatran (150 mg twice daily) was used in
the EINSTEIN and RE-SONATE studies.
Dabigatran is the only DOAC that has been compared
with warfarin for extended VTE prevention in the RE-
MEDY trial [51]. Dabigatran was non-inferior to war-
farin in prevention of recurrent VTE (1.8 versus 1.3 %,
hazard ratio [HR] 1.44; 95 % CI, 0.78–2.64) and had a
significantly lower rate of major bleeding or CRNMB
(HR 0.54; 95 % CI, 0.41–0.71). These results demonstrated
that DOACs are effective in secondary VTE prevention
with no significant increase in major bleeding. The ACCP
guidelines recommend no change in the choice of anti-
coagulant agent in patients who need extended anticoagu-
lation after the first 3 months of therapy [21]. Given the
observed lower bleeding risk, the dose of apixaban may be
reduced to 2.5 mg twice daily after the initial treatment.
Aspirin has been also evaluated in secondary VTE pre-
vention in patients with first unprovoked VTE who have
completed anticoagulant treatment. In this setting, ran-
domized trials and a meta-analysis reported a 30 % re-
duction in rates of recurrent VTE compared to placebo
or observation [52–55]. The ACCP guidelines suggest
that aspirin is an available option in patients with unpro-
voked VTE that are stopping anticoagulant therapy if
there are no contraindications to use of aspirin [21].
However, aspirin is not recommended as an alternative
to anticoagulant therapy [21].
Treatment of VTE in special situations
Management of sub-segmental pulmonary embolism
The increase in utilization of a highly sensitive com-
puted tomography pulmonary angiography (CTPA) has
led to detection of incidental asymptomatic PE or small
sub-segmental PE [56]. Whether or not patients with
sub-segmental pulmonary embolism (SSPE) should be
anticoagulated is controversial. It is unclear whether the
SSPE detected by CTPA are artifacts and therefore false
positive [57]. Furthermore, an isolated SSPE likely does
not have the same risk of progression or VTE recurrence
as a single segmental or lobar PE [57]. There are cur-
rently no published randomized trials for treatment of
patients with SSPE. Retrospective studies have reported
VTE recurrence in only a small number of patients with
SSPE and without DVT, who were not anticoagulated.
Table 4 Comparison of extended duration DOAC trials
Trial Name EINSTEIN-EXTENSION AMPLIFY-EXT RE-MEDY RE-SONATE
Year of Publication [Ref] 2010 [17] 2013 [50] 2013 [51] 2013 [51]
Design Double-blinded Double-blinded Double-blinded Double-blinded
Comparison Arm Placebo Placebo Warfarin Placebo
Number of Patients 1197 2486 2866 1353
Treatment Protocol Rivaroxaban 20 mg
once daily






Duration of Therapy (months) 6 to12 12 6 to 36 6
Primary Efficacy Outcome
DOAC vs VKA or Placebo (%)
Recurrent symptomatic
VTE: 1.3a vs 7.1
Recurrent symptomatic
VTE or all-cause mortality:
3.8a vs 4.2a vs 11.6
Recurrent symptomatic
VTE or related mortality:
1.8a vs 1.3
Recurrent symptomatic
VTE or related mortality:
0.4a vs 5.6
Major Bleeding DOAC vs
VKA or Placebo (%)
0.7 vs 0 0.2 vs 0.1 vs 0.5 0.9 vs 1.8 0.3 vs 0
Major and CRNM Bleeding
DOAC vs VKA or Placebo (%)
6.0a vs 1.2 3.2 vs 4.3 vs 2.7 5.6a vs 10.2 5.3a vs 1.8
DOAC direct oral anticoagulant, CRNM clinically relevant non-major, DOAC direct oral anticoagulants, VKA vitamin K antagonists, VTE venous thromboembolism
aStatistically significant difference between the two groups
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[57, 58]. Details of these retrospective studies are sum-
marized in Table 5 [59–65]. However, another retro-
spective study showed that patients with SSPE have
similar rate of VTE recurrence as patients with larger PE
during 3 months of anticoagulation [66]. The ACCP
guidelines suggest performing bilateral ultrasounds to
exclude proximal DVT before a decision is made not to
treat a patient with SSPE [21]. If a DVT is detected then
the patient should receive anticoagulation. However, if
no proximal DVT is detected the guidelines suggest that
the clinician assesses risk factors for VTE recurrence or
progression and considers anticoagulation for those with
high risk of VTE recurrence (e.g., recent surgery, im-
mobilization, active cancer, previous history of VTE)
[21]. Future prospective studies are needed to determine
the optimal management strategy for patients with SSPE
and no detected proximal DVT.
Role of inferior vena cava filter in management of acute
venous thromboembolism
Inferior vena cava (IVC) filters are typically used in pa-
tients with an acute VTE and an absolute contraindica-
tion to anticoagulation (e.g., concurrent active bleeding)
[67]. The IVC filter is removed once the bleeding risk is
low and anticoagulation is given [14]. In patients with
acute VTE already on anticoagulation with no absolute
contraindications, studies suggest that there is lack of
benefit to use of IVC filters in addition to anticoagula-
tion [68–72]. In the PREPIC 1 trial, 400 patients with
proximal DVT were randomized to either anticoagula-
tion alone or anticoagulation plus IVC filter placement
[68]. The initial 2-year PREPIC 1 study and a subse-
quently published 8-year follow-up reported that IVC
filter insertion was associated with a reduction in the
initial rate of PE, increase in the rate of DVT, and no
difference in mortality [68, 69]. The PREPIC 2 trial
examined the adjuvant role of IVC filters in patients
with PE who received either anticoagulation alone or
anticoagulation plus an IVC filter [70]. The filter was
removed at 3 months. There was no difference in the rates
of recurrent VTE or mortality between the two groups
[70]. In addition to lack of benefit, IVC filters are associ-
ated with complications including IVC filter thrombosis,
DVT, and guide wire entrapment [71, 72]. The ACCP
guidelines recommend against the use of IVC filters in
patients on anticoagulation for acute VTE [21].
Conclusions
VTE is a major cause of morbidity and mortality. DOACs
are suggested over VKA for acute and long-term treatment
of VTE in patients without cancer, as they have been shown
to be as effective as VKA in reducing VTE recurrence and
associated with significantly less major bleeding. Future
studies are needed to assess their safety and efficacy in out-
patient treatment of acute VTE. LMWH is the current
standard of care for treatment of VTE in cancer patients.
Randomized trials are ongoing to examine the non-
inferiority of DOACs versus LMWH in cancer patients.
Lastly, it is currently unclear whether or not to treat pa-
tients with SSPE and no proximal DVT; future prospective
studies are needed to examine different management strat-
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Year of Publication [Ref] 2002 [59] 2005 [60] 2010 [61] 2012 [62] 2014 [63] 2015 [64] 2016 [65]
Method of Detection SDCT MDCT MDCT MDCT MDCT MDCT V/P SPECT
Number of Patient with Positive CTPA 360 499 1463 724 NAb 550 NAb
Number of Patients with SSPE n/N (%) 12 (3.3) 67 (13.4) 93 (6.4) 70 (9.6) 32 (100) 82 (15) 54 (100)
Number of Untreated SSPE (%) 9 (75) 25 (37.3) 22 (22.9) 18 (25.7) 12 (37.5) 39 (47.6) 54 (100)
VTE (%) 0 0 0 0 0 0 4a
CTPA computed tomography pulmonary angiography, NA not applicable, MDCTmulti-detector computed tomography pulmonary angiography, SDCT single-detector
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